Abstract
Early studies have shown how aberrantly expressed microRNAs are a hallmark of several diseases like cancer. MicroRNA expression profiling was shown to be associated with tumour development, progression and response to therapy, suggesting their possible use as diagnostic, prognostic and predictive biomarkers. Moreover, based on the increasing number of studies demonstrating that microRNAs can function as potential oncogenes or oncosuppressor genes, with the goal to improve disease response and increase cure rates, miRNA-based anticancer therapies have recently been exploited, either alone or in combination with current targeted therapies. The advantage of using microRNA approaches is based on its ability to concurrently target multiple effectors of pathways involved in cell differentiation, proliferation and survival. Here, we review our current knowledge about the involvement of microRNAs in cancer, and their potential as diagnostic, prognostic and therapeutic tools.
| Original language | English |
|---|---|
| Pages (from-to) | 143-159 |
| Number of pages | 17 |
| Journal | EMBO Molecular Medicine |
| Volume | 4 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 2012 |
Fingerprint
Keywords
- Biomarkers
- Diagnostics
- Human cancer
- MicroRNAs
- Therapeutic impact
ASJC Scopus subject areas
- Molecular Medicine
Cite this
MicroRNA dysregulation in cancer : Diagnostics, monitoring and therapeutics. A comprehensive review. / Iorio, Marilena V.; Croce, Carlo M.
In: EMBO Molecular Medicine, Vol. 4, No. 3, 03.2012, p. 143-159.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - MicroRNA dysregulation in cancer
T2 - Diagnostics, monitoring and therapeutics. A comprehensive review
AU - Iorio, Marilena V.
AU - Croce, Carlo M.
PY - 2012/3
Y1 - 2012/3
N2 - Early studies have shown how aberrantly expressed microRNAs are a hallmark of several diseases like cancer. MicroRNA expression profiling was shown to be associated with tumour development, progression and response to therapy, suggesting their possible use as diagnostic, prognostic and predictive biomarkers. Moreover, based on the increasing number of studies demonstrating that microRNAs can function as potential oncogenes or oncosuppressor genes, with the goal to improve disease response and increase cure rates, miRNA-based anticancer therapies have recently been exploited, either alone or in combination with current targeted therapies. The advantage of using microRNA approaches is based on its ability to concurrently target multiple effectors of pathways involved in cell differentiation, proliferation and survival. Here, we review our current knowledge about the involvement of microRNAs in cancer, and their potential as diagnostic, prognostic and therapeutic tools.
AB - Early studies have shown how aberrantly expressed microRNAs are a hallmark of several diseases like cancer. MicroRNA expression profiling was shown to be associated with tumour development, progression and response to therapy, suggesting their possible use as diagnostic, prognostic and predictive biomarkers. Moreover, based on the increasing number of studies demonstrating that microRNAs can function as potential oncogenes or oncosuppressor genes, with the goal to improve disease response and increase cure rates, miRNA-based anticancer therapies have recently been exploited, either alone or in combination with current targeted therapies. The advantage of using microRNA approaches is based on its ability to concurrently target multiple effectors of pathways involved in cell differentiation, proliferation and survival. Here, we review our current knowledge about the involvement of microRNAs in cancer, and their potential as diagnostic, prognostic and therapeutic tools.
KW - Biomarkers
KW - Diagnostics
KW - Human cancer
KW - MicroRNAs
KW - Therapeutic impact
UR - http://www.scopus.com/inward/record.url?scp=84858126071&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84858126071&partnerID=8YFLogxK
U2 - 10.1002/emmm.201100209
DO - 10.1002/emmm.201100209
M3 - Article
C2 - 22351564
AN - SCOPUS:84858126071
VL - 4
SP - 143
EP - 159
JO - EMBO Molecular Medicine
JF - EMBO Molecular Medicine
SN - 1757-4676
IS - 3
ER -